Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil
Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) has received a GMP certification for its Barrie, Ontario facility from ANVISA, the governing body of Brazil's pharmaceutical industry.
MediPharm Labs Corp.（多伦多证券交易所股票代码：LABS）（OTCQB: MIF）（FSE: MLZ）已获得巴西制药行业管理机构ANVISA颁发的安大略省巴里工厂的GMP认证。
This is MediPharm's latest approval, following GMP certifications from the FDA, European Union and Australia's TGA, MediPharm also holds a drug establishment license from Health Canada.
这是MediPharm的最新批准，继美国食品药品管理局、欧盟和澳大利亚TGA的GMP认证之后，MediPharm还持有加拿大卫生部颁发的药品机构许可证。
The Toronto-based company is now positioned to produce both API and end products for Brazilian medical cannabis patients.
这家总部位于多伦多的公司现在有能力为巴西医用大麻患者生产原料药和最终产品。
According to a 2023 report by industry observer Kaya Mind, the Brazilian medical cannabis market is projected to reach CA$380 million ($281.2 million) in 2025.
根据行业观察家Kaya Mind在2023年发布的一份报告，预计到2025年，巴西医用大麻市场将达到3.8亿加元（合2.812亿美元）。
See also: New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
另见：新的CBD和四氢大麻酚大麻油现已从加拿大运往澳大利亚
"This GMP certification from Brazil strengthens MediPharm's position as one of the most pharmaceutically focused medical cannabis companies in the world," said David Pidduck, MediPharm Labs CEO. Whether it is the production of cannabis-based drug research, international cannabis medical programs or future marketable cannabis drugs, MediPharm has invested in and executed the development of global pharmaceutical and medical channels.
MediPharm Labs首席执行官戴维·皮德杜克表示：“巴西的这项GMP认证巩固了MediPharm作为世界上最专注于制药的医用大麻公司之一的地位。”无论是生产以大麻为基础的药物研究、国际大麻医疗项目还是未来的可销售的大麻药物，MediPharm都投资并执行了全球制药和医疗渠道的开发。
MediPharm Labs currently manufactures two medical cannabis products with full ANVISA product authorization under Brazil's Resolution 327/19. Additional product authorizations are currently under review with ANVISA. In addition to existing Brazilian customers, the company entered into a supply agreement with a top-tier generic pharmaceutical company in Brazil in July 2023.
根据巴西第327/19号决议，MediPharm Labs目前生产两种获得ANVISA产品全面授权的医用大麻产品。ANVISA目前正在审查其他产品授权。除了现有的巴西客户外，该公司还于2023年7月与巴西的一家顶级仿制药公司签订了供应协议。
In September 2020, MediPharm Labs confirmed a partnership with a Rio de Janeiro-based distributor. Under that deal, MedPharm Labs provides a wide range of cannabis concentrate formats for formulated products later distributed by XLR8 BRAZIL.
2020年9月，MediPharm Labs确认与一家位于里约热内卢的分销商建立合作伙伴关系。根据该协议，MedPharm Labs为后来由XLR8 BRAZIL分销的配方产品提供各种大麻浓缩物形式。
Now read: MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
立即阅读：尽管连续下跌，但MediPharm Labs仍达到850万加元，2023年第三季度财务报告中有更多相关信息
MEDIF Price Action
MEDIF 价格走势
MediPharm's shares traded 2.6923% higher at $0.0534 per share after the market close on Tuesday.
周二收盘后，MediPharm的股价上涨2.6923％，至每股0.0534美元。
Benzinga Cannabis Conferences are coming to Los Angeles. Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on February 22. Connect with top industry leaders, gain insider insights into the investment landscape and shape the evolving markets in California and beyond. Don't miss this chance to be at the forefront of the cannabis industry's growth and innovation! Join now.
Benzinga大麻会议即将在洛杉矶举行。加入 “Benzinga大麻市场聚焦：加州”，在2月22日在卡尔弗城举行的顶级社交活动上解锁大麻的未来。与顶级行业领导者建立联系，获得对投资格局的内幕见解，塑造加利福尼亚及其他地区不断变化的市场。千万不要错过这个站在大麻行业增长和创新最前沿的机会！立即加入。
译文内容由第三方软件翻译。